Peginterferon α‐2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients
Makoto Kuboki(Kawasaki Medical School), Takahiro Sakai(Japanese Red Cross Society, Japan), Tadao Okuno(Akashi Municipal City Hospital), Hiromitsu Kumada(Toranomon Hospital), Kendo Kiyosawa(Aizawa Hospital), Norio Hayashi(The University of Osaka), Shiro Iino(University of Fukui), Masao Omata(University of Yamanashi Hospital)
Cited by 60
Related Papers
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|Hepatology International|2017|2.2k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
|Hepatology|1990|1.2k
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573